PEX19 antibodies are immunological tools designed to detect and study the PEX19 protein, which functions as:
A cytosolic chaperone for peroxisomal membrane proteins (PMPs) .
An import receptor for PMPs, facilitating their insertion into peroxisomal membranes .
A regulator of peroxisome biogenesis disorders (PBDs), including Zellweger syndrome .
No validated "PEX19-2" isoform or antibody is documented in UniProt, GeneCards, or peer-reviewed studies. Existing antibodies target canonical PEX19 and are critical for studying peroxisome dynamics and associated diseases.
PEX19 interacts with the influenza A virus M2 protein, inhibiting viral replication by reducing peroxisome abundance and disrupting ROS metabolism .
Knockdown of PEX19 in A549 cells increased viral replication and oxidative stress .
PEX19 deficiency disrupts peroxisome assembly, leading to cytosolic catalase accumulation and Zellweger syndrome .
Antibodies like ab137072 confirmed PEX19’s absence in CRISPR-edited PEX19⁻/⁻ cells via Western blot and immunofluorescence .
PEX19 knockout cells (PEX19⁻/⁻) show defective lipid droplet turnover under catabolic conditions, independent of peroxisome function .
Antibody 14713-1-AP detected PEX19 in lipid metabolic studies using human liver cancer tissue .
Band Discrepancies: Multiple antibodies report higher observed molecular weights (~35–40 kDa) than predicted (33 kDa), likely due to post-translational modifications .
Cross-Reactivity: Antibody 14713-1-AP shows reactivity with Arabidopsis, suggesting conserved epitopes .
Buffers: Antigen retrieval with TE buffer (pH 9.0) optimizes IHC detection .